FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileVaxart, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VXRT
Vaxart, Inc. Stock AnalysisComprehensive stock analysis for Vaxart, Inc. (VXRT) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisVXRT
VXRT
Vaxart, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
VXRT
  1. Home
  2. Stocks
  3. Vaxart, Inc.

Vaxart, Inc.

🇺🇸VXRT•OTC

Vaxart, Inc.

🇺🇸VXRT•OTC
Market cap
$129.30M
Sentiment

Your view on VXRT

Mkt Cap
$129.30M
Sentiment
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Vaxart, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Steven Lo
Headquarters
170 Harbor Way, South San Francisco, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Steven Lo
Headquarters
170 Harbor Way, South San Francisco, CA, US
Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.

The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.

4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.

It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Financial Data

Stock Data

Price chart, volume, and trading data.

FRC Fair Value Algorithm

What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.

About this section

Fair value for Vaxart, Inc. from FRC's valuation model, read against the market price. VXRT last traded at $0.53, 3.0× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Vaxart, Inc.. Starting points for Vaxart, Inc.: P/E 3.0, EPS $0.12, beta 1.09 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Vaxart, Inc.. Vaxart, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Vaxart, Inc.. Trailing twelve-month EPS for Vaxart, Inc. stands at $0.12. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Third partyAs of Nov 18, 2026 · USD

Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.

Current price

—

live quote

Analysts' target

$2.00

average of analysts' targets

 

$2.00

Low $2.00

Median $2.00

High $2.00

 

Analyst Ratings

Buy3 ratings
  • Strong Buy0
  • Buy3
  • Hold0
  • Sell0
  • Strong Sell0

Earnings Estimate

EPSCurrent QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$0.04-$0.05-$0.42
Low estimate$0.04-$0.05-$0.42
High estimate$0.04-$0.05-$0.42
No. of analysts111
Year-ago EPS-$0.111$0.071—
Growth———

1Year-ago EPS includes one-time items; growth not shown.

Revenue Estimate

RevenueCurrent QtrDec 2026Current YearFY Dec 2026Next YearFY Dec 2027
Avg. estimate$41.60M$118.60M$2.35M
Low estimate$41.60M$118.60M$2.35M
High estimate$41.60M$118.60M$2.35M
No. of analysts111
Year-ago revenue$104.24M$237.26M—
Growth-60.1%-50.0%—
Recent analyst actions10 rating and price-target changes, latest Mar 27, 2025 — with the analyst, firm and source

Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 18, 2026. Not FRC research or a recommendation.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Vaxart, Inc.. Vaxart, Inc. has reported as a listed company since 1981. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold VXRT20 companies
Compare VXRT with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis

Peer companies

Market cap

  • ARCTArcturus Therapeutics Holdings Inc.Biotechnology$240M
  • BVNRYBavarian Nordic A/SBiotechnology$2.4B
  • GOVXGeoVax Labs, Inc.Biotechnology$850,325
  • INOInovio Pharmaceuticals, Inc.Biotechnology$97M
  • MRNAModerna, Inc.Biotechnology$87.1B
  • NVAXNovavax, Inc.Biotechnology$1.3B
  • OCGNOcugen, Inc.Biotechnology$262M
  • PCVXVaxcyte, Inc.Biotechnology$9.8B

More Biotechnology companies

  • GLMDGalmed Pharmaceuticals Ltd.NASDAQ$5M
  • GLOW.CNGlow Lifetech Corp.CNQ$11M
  • GLPGFGalapagos N.V.OTC$2.2B
  • GLSHQGelesis Holdings, Inc.OTC$7,334
  • DBVTDBV Technologies S.A.NASDAQ$246M
  • DFTXDefinium Therapeutics, Inc.NASDAQ$4.1B
  • DMACDiaMedica Therapeutics Inc.NASDAQ$449M
  • DMED.CNDiagnamed Holdings Corp.CNQ$6M
  • DMRADamora Therapeutics, Inc.NASDAQ$1.4B
  • DMTRF3-D Matrix, Ltd.OTC$285M
  • DNAGinkgo Bioworks Holdings, Inc.NYSE$551M
  • DNAGDNAPrint Genomics, Inc.OTC$6,446
Open Comparable Analysis
Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold Vaxart, Inc., and how their positions are changing. At a $129.3M market value, institutional positions materially move Vaxart, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by Vaxart, Inc. executives and directors. Shares of Vaxart, Inc. have traded between $0.26 and $0.98 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Vaxart, Inc.. Coverage tracks Vaxart, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Vaxart, Inc.

VXRT Analysis
Strong
Past5
Growth5
Health5
Profit5
Value5

News

Latest Market News